Timing and intensity of proton pump inhibitor exposure hampers overall survival in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective cohort study | Synapse
March 3, 2026Open Access
Timing and intensity of proton pump inhibitor exposure hampers overall survival in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective cohort study
Puntos clave
Proton pump inhibitor use correlates with reduced overall survival in lung cancer patients, indicating a significant effect.
Patients exposed to intensive proton pump inhibitor treatment show a notable decline in overall survival rates.
Retrospective cohort analysis conducted to explore the relationship between proton pump inhibitors and survival outcomes.
Findings underline the importance of evaluating proton pump inhibitor prescriptions for patients receiving immune checkpoint inhibitors.
Resumen
PPI use around ICI initiation as well as PPI treatment intensity over a wider period was associated with reduced OS. Efforts should be made to streamline PPI use.